OPKO Health is a medical test and medication company focused on diagnostics and pharmaceuticals. The company develops treatments for secondary hyperparathyroidism, and has recently finished the patient recruitment for a Phase III trial against insufficiency in Vitamin D. The company is a publicly traded company on NYSE under the symbol "OPK". It acquired Laboratorio Arama de Uruguay in 2014 and is seeking to expand its presence in Uruguay and Argentina. OPKO Health Incorporation focuses on production of cardiovascular products, vaccines, hormones, antibiotics, gastrointestinal products, and eye care. The company operates in the U.S., Chile, Israel, Mexico, Uruguay, and Spain. The productions of OPKO Health Incorporation include mainly two segments: Pharmaceuticals and Diagnostics. The company is recently expanding collaboration with Bristol-Myers Squibb Co. on diagnostic test technology, which involves blood tests identifying biomarkers of diseases.